Nilofer Azad, MD (IMAGE)

ECOG-ACRIN Cancer Research Group

Nilofer Azad, MD

Caption

'The confirmed overall response rate for nivolumab in tumors with DNA mismatch repair deficiencies was 36% -- or 15 of 42 patients with cancers other than colon.'

Credit

Johns Hopkins Kimmel Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.